SUBSCRIBE
SUBSCRIBE

Mark

File folder with Merger and Acquisition and financial graphs. Business concept
Deals
In Second Gene Therapy Buy of the Year, Novartis Acquires AveXis for $8.7B
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
April 9, 2018
 · 
3 min read
 · 
Mark
Ovarian cancer vaccine under research.
Drug Development
On Target Labs: Late-Stage Ovarian Cancer Detection Trial Underway
On Target Laboratories announced that the first patient was treated in its Phase III trial of OTL38 in detecting ovarian cancer. Linked with a near-infrared dye, OTL38 allows surgeons to visually identify cancer cells that can guide them in removing the cancer tissue.
April 5, 2018
 · 
2 min read
 · 
Mark